DUBLIN–(BUSINESS WIRE)–The “Global ANCA Vasculitis – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “ANCA Vasculitis – Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in ANCA Vasculitis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the ANCA Vasculitis pipeline landscape is provided which includes the disease overview and ANCA Vasculitis treatment guidelines. The assessment part of the report embraces, in depth ANCA Vasculitis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, ANCA Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for ANCA Vasculitis.
- In the coming years, the ANCA Vasculitis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence ANCA Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the ANCA Vasculitis treatment market. Several potential therapies for ANCA Vasculitis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the ANCA Vasculitis market size in the coming years.
ANCA Vasculitis Emerging Drugs Chapters
This segment of the ANCA Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ANCA Vasculitis Emerging Drugs
Depemokimab: GlaxoSmithKline
Depemokimab (GSK’294) is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity and long-acting suppression of IL-5 function. IL-5 is the major cytokine responsible for the proliferation, activation and survival of eosinophils, making it a proven treatment target for severe asthma patients with higher levels of eosinophils. Currently, it is in Phase III stage of clinical trial evaluation to treat Eosinophilic Granulomatosis with Polyangiitis.
Benralizumab: AstraZeneca
Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking, signal transduction. Besides, it is an afucosylated IgG which gives it high affinity for the FcyRIIIa receptor in natural killer cells, macrophages and neutrophils.1 Benralizumab, FDA approved on November 14, 2017, was developed by MedImmune, the AstraZeneca’s global biologic research and development arm. Currently, it is in Phase III stage of clinical trial evaluation to treat Eosinophilic Granulomatosis with Polyangiitis.
ANCA Vasculitis: Therapeutic Assessment
This segment of the report provides insights about the different ANCA Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in ANCA Vasculitis
There are approx. 8+ key companies which are developing the therapies for ANCA Vasculitis. The companies which have their ANCA Vasculitis drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.
Phases
This report covers around 8+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
ANCA Vasculitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses ANCA Vasculitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging ANCA Vasculitis drugs.
ANCA Vasculitis Report Insights
- ANCA Vasculitis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
ANCA Vasculitis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- GlaxoSmithKline
- AstraZeneca
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Bristol-Myers Squibb
- InflaRx N.V.
- Chia Tai Tianqing Pharmaceutical
- Visterra
Key Products
- Depemokimab
- Benralizumab
- BDB-001
- Abatacept
- Vilobelimab
- Belimumab
- Meperizumab
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/v9nn0n
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900